Records 1 - 8
| Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity.
Metabolism: clinical and experimental 2022 Jun 133 155237.
Valenzuela-Vallejo Laura, Chrysafi Pavlina, Bello-Ramos Jenny, Bsata Shahd, Mantzoros Christos
| Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation.
Nutrients 2021 Oct 13 (11): .
Chen Yu-Mu, Lai Chien-Hao, Lin Chiung-Yu, Tsai Yi-Hsuan, Chang Ya-Chun, Chen Hung-Chen, Tseng Chia-Cheng, Chang Huang-Chih, Huang Kuo-Tung, Chen Yung-Che, Fang Wen-Feng, Wang Chin-Chou, Chao Tung-Ying, Lin Meng-Ch
| Five-year survival and prognostic factors according to histology in 6101 non-small-cell lung cancer patients.
Respiratory medicine and research 2019 Oct 77 46-54.
Molinier O, Goupil F, Debieuvre D, Auliac J-B, Jeandeau S, Lacroix S, Martin F, Grivaux
| Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI.
Journal of Cancer 2018 9 (3): 528-534.
Lin Liping, Zhao Juanjuan, Hu Jiazhu, Huang Fuxi, Han Jianjun, He Yan, Cao Xiaolo
| Risk factors and prognosis value of venous thromboembolism in patients with advanced non-small cell lung cancer: a case-control study.
Journal of thoracic disease 2017 Dec 9 (12): 5068-5074.
Shen Qian, Dong Xiaoqi, Tang Xiaoping, Zhou Jianyi
| AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients.
Molecular cancer therapeutics 2016 Aug .
Xu Xiao, Mao Long, Xu Wanhong, Tang Wei, Zhang Xiaoying, Xi Biao, Xu Rongda, Fang Xin, Liu Jia, Fang Ce, Zhao Li, Wang Xiaobo, Jiang Ji, Hu Pei, Zhao Hongyun, Zhang
| Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.
Oncology reports 2013 Sep 30 (3): 1463-72.
Krawczyk Pawe?, Kowalski Dariusz M, Krawczyk Kamila Wojas, Szczyrek Micha?, Mlak Rados?aw, Rolski Andrzej, Szudy Aneta, Kieszko Robert, Winiarczyk Kinga, Milanowski Janusz, Krzakowski Maci
| Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010 Sep 5 (9): 1382-90.
Ready Neal, Jänne Pasi A, Bogart Jeffrey, Dipetrillo Thomas, Garst Jennifer, Graziano Stephen, Gu Lin, Wang Xiaofei, Green Mark R, Vokes Everett E,